CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：T cell redirecting therapy for relapsed multiple myeloma.
T cell redirecting therapy for relapsed multiple myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
近年来，免疫调节药物、蛋白酶体抑制剂和靶向 CD38 的单克隆抗体显著改善了多发性骨髓瘤患者的总体结局。尽管治疗已有进展，复发仍很常见，且直到近期此类患者的预后仍不理想。CAR-T 和 T 细胞衔接器（TCE）获批后，三类及五类药物耐药患者的生存显著改善。本文综述这些新型免疫治疗药物相关临床结局及毒性、其在多发性骨髓瘤治疗中的作用和最佳序贯安排，并讨论患者管理中支持治疗的重要性。最后，作者展望复发性多发性骨髓瘤免疫治疗的新兴进展。
In recent years, the utilization of immunomodulatory drugs, proteasome inhibitors and CD38 targeting monoclonal antibodies has led to significant improvements in the overall outcomes of patients with multiple myeloma. Despite these advances, relapse remains common, and until recently, the prognosis of such patients was guarded.
The approval of chimeric antigen receptor (CAR) T-cells and T-cell engagers (TCE) have considerably improved the survival in these patients with triple and penta-class refractory disease. This paper reviews the clinical outcomes associated with these novel immunotherapeutic agents, including their associated toxicities, their role and optimal sequencing within the treatment landscape of multiple myeloma. The importance of supportive care in managing these patients will be discussed.
Finally, we offer a perspective on emerging developments in the immunotherapy of relapsed multiple myeloma.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
